|
May 28, 2024
|
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
|
|
|
May 13, 2024
|
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
|
|
|
May 13, 2024
|
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
|
|
|
Mar 14, 2024
|
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
|
|
|
Feb 22, 2024
|
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
|
|
|
Jan 22, 2024
|
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
|
|
|
Jan 03, 2024
|
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson's diseases
|
|